The treatment landscape for atopic dermatitis (AD) in the United States is undergoing a revolution. Since 2017, six agents have been approved by the FDA (four of these since the start of 2021),…
The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Clarivate Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as…
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
For more than a decade, AbbVie’s Restasis was the only FDA-approved therapy for dry eye disease (DED) until the launch of Novartis’s Xiidra in 2016, followed by Restasis MultiDose, Sun…